Vertex Pharmaceuticals Incorporated (VRTX) Analyst Ratings & Price Targets

Vertex Pharmaceuticals Incorporated

VRTX · Nasdaq

Analyst Consensus

Buy

27 analysts

$488

Current

—

Low

$560

Average

—

High

Average target implies +14.74% versus the current price.

The ratings synthesis for VRTX has not been generated yet.

Rating Actions

No individual rating actions have been captured for VRTXyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

CANACCORD GENUI

CANTOR FITZGERA

DBS BANK

EVERCORE ISI

GUGGENHEIM SEC.

H C WAINWRIGHT

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MAXIM GROUP,LLC

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: VRTX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: Nasdaq

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London.

Analyst Consensus

See all

Buy

27 analysts

$488

Current

—

Low

$560

Average

—

High

Average target implies +14.74% versus the current price.

Earnings History

BeatMissNo estimate

Vertex Pharmaceuticals Incorporated

Analyst Consensus

Rating Actions

Covering Firms

Peers